Roundtable on BKTis in Chronic Lymphocytic Leukemia

Findings from an AMCP Market Insights Program

Chronic lymphocytic leukemia (CLL) is characterized by a progressive accumulation of leukemia cells in the peripheral blood, bone marrow, and lymphoid tissues. Bruton tyrosine kinase inhibitors (BTKis) are a preferred treatment of patients with CLL. Due to the relatively recent growth in the number of treatment options for CLL, especially among BTKis, and ongoing research into treating this condition, it is likely that interest among payers in applying more rigorous management strategies will grow as well.

In September 2022, AMCP convened an expert panel of managed care stakeholders to better understand the clinical dynamics of treatment choice in patients with CLL and the key management considerations in CLL with a focus on BTKis. The program was conducted in a double-blind format on in September 2022. Panelists included representatives from national and regional health plans, health systems, integrated delivery networks, and pharmacy benefit management. With a guest clinical expert from a leading academic center specializing in the treatment of CLL, participants discussed the role of individual BTKis including important distinctions in their safety, efficacy, and tolerability, and the attributes of CLL and its treatments considered when making management decisions.